PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

Dosing Through CRRT: Delivered Clearance, Not eGFR, Should Drive Drug Dosing

continuous renal replacement therapyCRRTpharmacokineticstherapeutic drug monitoringmodel-informed precision dosingbeta-lactamsvancomycinaminoglycosideslinezolidcritical careAKInarrative reviewdose optimization Pharmacokinetics / TDM

Background Information

CRRT demands precise drug dosing adjustments in critical care settings.

CRRT affects drug clearance in critically ill patients, requiring precise dosing to optimize therapeutic outcomes. The review outlines drug, patient, and CRRT factors influencing drug clearance, and proposes an eight-step dosing framework. This review offers a practical approach to dosing during CRRT, but requires clinical judgment and additional validation for broader application. Effective drug dosing during CRRT is complex and requires a structured, multifactorial approach.

📊 Deep Analysis Available
Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report. Cancel anytime.
Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.

Authors: Pui MC, Lazar AE, Szederjesi J, Branea OE, Butiulca M, Cehan VD, Straistă M, Azamfirei L

Citation: Pui MC, Lazar AE, Szederjesi J, et al. Drug Dosing During Continuous Renal Replacement Therapy in Critically Ill Patients: A Practical Narrative Review. Pharmaceutics. 2026;18(10). doi:10.3390/pharmaceutics18101320

Article Links: PubMed · Journal / DOI · Free Full Text (PMC)

🎓
Reviewed by a licensed pharmacist
Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.
Accurate and up-to-date information is our highest priority.
If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.
Thanks for the feedback!
🔒
Deep Analysis: Subscribers Only
Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.
Executive Summary
Study Design
Patient Population
Primary Outcomes
Secondary Outcomes & Safety Profile
Pharmacist Implications
Clinical Pearls
Limitations
Controversies & Evidence Gaps
Cost & Logistics
Founding member rate
$8/month. Cancel anytime.

One subscription unlocks this analysis and every other one we publish, plus Practice Signals, PDF reports, and GRADE evidence grades.

Subscribe for $8/month → Read this one free →
Free account, no credit card. Includes 1 full deep analysis every month.
Or $79/year. Founding members keep this rate for as long as they stay subscribed. Cancel anytime from your Account page.